The pharmacokinetics of digoxin in newborn and adult sheep

  • William BermanJr.
  • Jude Musselman
  • Romana Shortencarrier
Article
First Online:
Received:
Revised:

Abstract

The pharmacokinetics of digoxin were determined in 12 ewes and 13 newborn sheep after bolus drug administration and under steady state drug conditions. After death, tissue distribution of digoxin was determined and normalized to plasma drug concentrations at steady state. Volume of distribution and total drug clearance were lower at steady state than the comparable variables calculated from bolus drug administration. No significant difference between ewes and newborns was shown for drug distribution half-life (0.72 vs. 0.76 hr), drug elimination halflife (15.2 vs. 13.7), or renal drug clearance (0.86 vs. 0.89 liters/kg/hr). Total drug clearance as well as the area derived and steady state volumes of distribution were higher in newborns than in ewes. Digoxin secretion into the urine was limited in newborns, as evidenced by a lower renal digoxin clearance to creatinine clearance ratio in newborns than in ewes (371 vs. 600%). The plasma concentration of digoxin at steady state correlated well with myocardial drug concentrations. Drug distribution was similar in both age groups; however, the tissue to plasma digoxin ratio in kidney was higher in newborns than in ewes (mean 469 vs. 263, respectively). Although agerelated differences in drug clearance and distribution volume existed, intersubject variation was substantial, and the demonstrated variations were not large enough to account for the high doses of digoxin used to treat congestive heart failure in immature subjects.

Key words

digoxin pharmacokinetics steady state kinetics age-related kinetics 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    W. Berman, Jr. and J. Musselman. The relationship of age to the metabolism and protein binding of digoxin in sheep.J. Pharmacol. Exp. Ther. 208:263–266 (1978).Google Scholar
  2. 2.
    F. I. Marcus. Current status of therapy with digoxin.Current Problems in Cardiology 59:1–41 (1979).Google Scholar
  3. 3.
    J. M. Neutze, J. D. Rutherford, and P. J. Hurley. Serum digoxin levels in neonates, infants and children with heart disease.N.Z. Med. J. 86:7–10 (1977).PubMedGoogle Scholar
  4. 4.
    G. Wettrell and K. E. Andersson. Clinical pharmacokinetics of digoxin in infants.Clin. Pharmacokin. 2:17–31 (1977).CrossRefGoogle Scholar
  5. 5.
    L. F. Soyka. Clinical pharmacology of digoxin.Pediatr. Clin. North Am. 19:241–256 (1972).PubMedGoogle Scholar
  6. 6.
    S. O. Sapin, E. Donoso, and S. Blumenthal. Digoxin dosage in infants.Pediatrics 18:730–738 (1956).PubMedGoogle Scholar
  7. 7.
    W. Berman, Jr., P. J. Ravenscroft, L. B. Sheiner, M. A. Heymann, K. L. Melmon, and A. M. Rudolph. Differential effects of digoxin at comparable concentrations in tissues of fetal and adult sheep.Circ. Res. 41:635–641 (1977).PubMedCrossRefGoogle Scholar
  8. 8.
    W. Berman, Jr., O. Dubynsky, V. Whitman, Z. Friedman, J. Maisels, and J. Musselman. Digoxin therapy in low-birth-weight infants with patent ductus arteriosus.J. Pediatr. 93:652–655 (1978).PubMedCrossRefGoogle Scholar
  9. 9.
    M. C. Rogers, J. T. Willerson, A. Goldblatt, and T. W. Smith. Serum digoxin concentrations in the human fetus, neonate and infant.N. Engl. J. Med. 287:1010–1014 (1972).PubMedCrossRefGoogle Scholar
  10. 10.
    A. Wollenberger, J. Jehl, and M. L. Karsh. Influence of age on the sensitivity of the guinea pig and its myocardium to ouabain.J. Pharmacol. Exp. Ther. 108:52 (1952).Google Scholar
  11. 11.
    K. H. Halloran, S. C. Schimpft, J. G. Nicolar, and N. S. Talner. Digitalis tolerance in young puppies.Pediatrics 46:730–736 (1970).PubMedGoogle Scholar
  12. 12.
    C. J. Hayes, V. P. Butler, and W. M. Gersony. Serum digoxin studies in infants and children.Pediatrics 52:561–567 (1973).PubMedGoogle Scholar
  13. 13.
    G. J. Kelliher and J. Roberts. Effect on age on the cardiotoxic action of digitalis.J. Pharmacol. Exp. Ther. 197:10–18 (1976).PubMedGoogle Scholar
  14. 14.
    W. Berman, Jr. Digitalis toxicity and serum levels.Pediatrics 63:503–504 (1979).PubMedGoogle Scholar
  15. 15.
    W. W. Pinsky, J. R. Jacobsen, P. C. Gillette, J. Adams, L. Monroe, and D. G. McNamara. Dosage of digoxin in premature infants.J. Pediatr. 96:639–642 (1979).CrossRefGoogle Scholar
  16. 16.
    T. Vargo, R. Lewis, J. Purdine, and A. Schwartz. Comparison between puppies and adult dogs following infusion of digoxin (abstract).Pediatr. Res. 8:335 (1974).CrossRefGoogle Scholar
  17. 17.
    R. D. White and P. S. Lietman. Commentary: a reappraisal of digitalis for infants with left-to-right shunts and “heart failure.”J. Pediatr. 92:867–870 (1978).PubMedCrossRefGoogle Scholar
  18. 18.
    J. R. Koup, D. J. Greenblatt, W. J. Jusko, T. W. Smith, and J. Koch-Weser. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.J. Pharmacokin. Biopharm. 3:181–192 (1975).CrossRefGoogle Scholar
  19. 19.
    P. L. Morselli, B. M. Assael, R. Gomeni, M. Mandelli, A. Marini, E. Reali, U. Visconti, and F. Sereni. Digoxin pharmacokinetics during human development. InBasic and Therapeutic Aspects of Perinatal Pharmacology. Raven Press, New York, 1975.Google Scholar
  20. 20.
    R. H. Reuning, R. A. Sams, and R. E. Notari. Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin.J. Clin, Pharmacol. 13:127–141 (1973).Google Scholar
  21. 21.
    S. A. Glantz, R. Kernoff, and R. H. Goldman. Age-related changes in ouabain pharmacology.Circ. Res. 39:407–414 (1976).PubMedCrossRefGoogle Scholar
  22. 22.
    S. Singh, S. Gadgil, and B. L. Mirkin. Age dependent factors influencing digoxin pharmacokinetics in the postnatal puppy.Res. Commun. Chem. Pathol. Pharmacol. 21:87–101 (1978).PubMedGoogle Scholar
  23. 23.
    H. Halkin, M. Radomsky, P. Millman, S. Almog, L. Blieden, and H. Boichis. Steady state serum concentrations and renal clearance of digoxin in neonates, infants and children.Eur. J. Clin. Pharmacol. 13:113–117 (1978).PubMedCrossRefGoogle Scholar
  24. 24.
    W. Berman, Jr., J. Musselman and R. Shortencarrier. The physiologic effects of digoxin under steady state drug conditions in newborn adult sheep.Circulation 62:1165–1171 (1980).PubMedCrossRefGoogle Scholar
  25. 25.
    P. M. Loughnan, D. S. Sitar, R. I. Ogilvie, and A. H. Neims. The two-compartment open-system kinetic model: a review of its clinical implications and applications.J. Pediatr. 88:869–873 (1976).PubMedCrossRefGoogle Scholar
  26. 26.
    D. J. Greenblatt and J. Koch-Weser. Clinical pharmacokinetics.N. Engl. J. Med. 293:702–705, 964–970 (1975).PubMedCrossRefGoogle Scholar
  27. 27.
    D. S. Miyada, V. Baysinger, S. Notrica, and R. M. Nokamaura. Albumin quantitation by dye binding and salt fractionation techniques.Clin. Chem. 18:52–56 (1972).PubMedGoogle Scholar
  28. 28.
    H. J. Gitelman. An improved automated procedure for the determinations of calcium in biological specimens.Anal. Biochem. 18:521–531 (1967).CrossRefGoogle Scholar
  29. 29.
    H. A. Teloh.Clinical Flame Photometry. Charles C Thomas, Springfield, Ill. 1959.Google Scholar
  30. 30.
    H. H. Taussky. A procedure increasing the specificity of the Jaffe reaction for the determination of creatine and creatinine in urine and plasma.Clin. Chim. Acta 1:210–224 (1956).PubMedCrossRefGoogle Scholar
  31. 31.
    G. W. Snedecor, and W. G. Cochran.Statistical Methods, 6th ed. The Iowa State University Press, Ames, Iowa, 1967.Google Scholar
  32. 32.
    P. L. Altaian and D. S. Dittmer (eds.).Biology Data Book, 2nd ed. Vol. III. Federation of American Societies for Experimental Biology, Bethesda, Md., 1974.Google Scholar
  33. 33.
    D. S. Lukas and A. G. De Martino. Binding of digitoxin and some related cardenolides to human plasma proteins.J. Clin. Invest. 48:1041–1053 (1969).PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    J. E. Doherty. Digitalis glycosides: pharmacokinetics and their clinical implications.Ann. Intern. Med. 79:229–238 (1973).PubMedCrossRefGoogle Scholar
  35. 35.
    J. E. Doherty, W. H. Perkins, and G. K. Mitchell. Tritiated digoxin studies in human subjects.Arch. Intern. Med. 108:531–539 (1961).PubMedCrossRefGoogle Scholar
  36. 36.
    W. T. Dungan, J. E. Doherty, G. Harvey, F. Char, and G. V. Dalrymple. Tritiated digoxin XVIII.Circulation 46:983–988 (1972).PubMedCrossRefGoogle Scholar
  37. 37.
    A. Hernandez, R. M. Burton, R. D. Pagtakhan, D. Goldring, and J. Aissie. Pharmacodynamics of3H-digoxin in infants.Pediatrics 44:418–428 (1969).PubMedGoogle Scholar
  38. 38.
    D. Lang and G. von Bernuth. Serum concentration and serum half-life of digoxin in premature and mature newborns.Pediatrics 59:902–906 (1977).PubMedGoogle Scholar
  39. 39.
    G. Wettrell. Digoxin therapy in infants.Acta Pediatr. Scand. 257:7–28 (1976).Google Scholar
  40. 40.
    G. Wettrell. Distribution and elimination of digoxin in infants.Eur. J. Clin. Pharmacol. 11:329–335 (1977).PubMedCrossRefGoogle Scholar
  41. 41.
    R. D. Okada, W. D. Hager, P. E. Graves, M. Mayersohn, D. G. Perrier, and F. I. Marcus. Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment.Circulation 58:1196–1203 (1978).PubMedCrossRefGoogle Scholar
  42. 42.
    E. Steiness. Renal tubular secretion of digoxin.Circulation 50:103–107 (1974).PubMedCrossRefGoogle Scholar
  43. 43.
    R. Gorodischer, W. J. Jusko, and S. J. Yaffe. Renal clearance of digoxin in young infants.Res. Commun. Chem. Pathol. Pharmacol. 16:363–374 (1977).PubMedGoogle Scholar
  44. 44.
    J. P. Guignard, A. Torrado, O. D. Cunha, and E. Gautier. Glomerular filtration rate in the first three weeks of life.J. Pediatr. 87:268–272 (1975).PubMedCrossRefGoogle Scholar
  45. 45.
    C. M. Edelmann and A. Spitzer. The maturing kidney.J. Pediatr. 75:509–519 (1969).PubMedCrossRefGoogle Scholar
  46. 46.
    J. Karjalainen, K. Ojala, and P. Reissel. Tissue concentrations of digoxin in an autopsy material.Acta Pharmacol. Toxicol. 34:385–390 (1974).CrossRefGoogle Scholar
  47. 47.
    J. Coltart, M. Howard, and D. Chamberlain. Myocardial and skeletal muscle concentrations of digoxin in patients on long-term therapy.Br. Med. J. 2:318–319 (1972).PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    D. Lang, R. Hofstetter, and G. von Bernuth. Post-mortem tissue and plasma concentrations of digoxin in newborns and infants.Eur. J. Pediatr. 128:151–161 (1978).PubMedCrossRefGoogle Scholar
  49. 49.
    P. W. Kim, R. W. Krasula, L. F. Soyka, and A. R. Hastreiter. Post-mortem tissue digoxin concentrations in infants and children.Circulation 52:1128–1131 (1975).PubMedCrossRefGoogle Scholar
  50. 50.
    R. Gorodischer, W. J. Jusko, and S. J. Yaffe. Tissue and erythrocyte distribution of digoxin in infants.Clin. Pharmacol. Ther. 19:256–263 (1976).PubMedGoogle Scholar
  51. 51.
    W. Shapiro. Correlative studies of serum digitalis levels and the arrhythmias of digitalis intoxication.Am. J. Cardiol. 41:852–859 (1978).PubMedCrossRefGoogle Scholar
  52. 52.
    J. A. Ingelfinger, and P. Goldman. The serum digitalis concentration-does it diagnose digitalis toxicity?N. Engl. J. Med. 294:867–870 (1976).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1982

Authors and Affiliations

  • William BermanJr.
    • 1
  • Jude Musselman
    • 1
  • Romana Shortencarrier
    • 1
  1. 1.Department of Pediatrics, Division of CardiologyUniversity of New Mexico, School of MedicineAlbuquerque

Personalised recommendations